Hematology and Covid-19
COVID-19 gives as complex medical manifestations, from flu-like signs and symptoms to a couple of organ failure and death. According to the prognosis and remedy protocol for novel coronavirus pneumonia posted through the National Health Commission of China, there are 4 severity tiers of COVID-19 primarily based totally at the medical manifestations: mild, moderate, intense, and essential disease. Severe, in particular essential, instances are normally complex through different organ dysfunctions, such as septic shock, coronary heart failure, and disseminated intravascular coagulation (DIC).
In medical practice, a few thrombotic headaches were mentioned, such as ischaemic limbs, strokes, and venous thromboembolism. Venous thromboembolism is not unusual place in sufferers with intense disease. Although numerous research mentioned that reduced platelet matter and improved D-dimer have been related to intense COVID-19 and excessive mortality, few research have systematically assessed haematological and coagulation parameters amongst sufferers with moderate, intense, and essential COVID-19
- Full blood count and biochemistry findings
- The emerging role of biomarkers procalcitonin, ferritin and C-reactive protein in the prognosis
- Coagulation complications
- Blood and hematopoietic stem cell donation
Related Conference of Hematology and Covid-19
Hematology and Covid-19 Conference Speakers
Recommended Sessions
- Acute and Chronic Lymphocytic Leukemia
- Bone Marrow Transplantation
- Development of Hematopoietic Progenitor and Stem Cells
- Digital imaging in Hematology
- Disorders of Vascular Bleeding
- Epigenetic Mechanisms: Emerging Therapeutic Targets for Blood Disorders
- Genetics, Genomics, and Epigenetics
- Genome Editing and Cellular Therapy
- Hematologic Malignancy
- Hematology and Covid-19
- Hematology-Oncology
- Hemoglobin and Iron Metabolism
- Hemoglobinopathies
- Hemophilia
- Hemostasis and Thrombosis
- Immunology and Immunotherapies
- Multiple Myeloma and Other Plasma Cell Disorders
- Myelodysplastic and Myeloproliferative Disorders
- Pediatric Hematology
- Pharmacology of Chemotherapy
- Radiation Oncology or Cancer Therapy
- Transfusion Medicine
- Types of Blood Disorders
Related Journals
Are you interested in
- Advances in Hematologic Malignancies - Blood Disorders 2025 (Italy)
- Advances in Hemostasis and Thrombosis - Blood Disorders 2025 (Italy)
- Biomarkers in Hematology and Oncology - Hematology Congress 2025 (Switzerland)
- Blood Disorders and the Immune System - Blood Disorders 2025 (Italy)
- Blood Disorders Diagnosis & Treatment - HEMATOLOGY 2025 (Spain)
- Blood Disorders in Aging Populations - Blood Disorders 2025 (Italy)
- Blood Disorders: Diagnosis and Treatment - Hematology Congress 2025 (Switzerland)
- Blood Transfusion - HEMATOLOGY 2025 (Spain)
- Cancer Genomics & Metabolomics - Hematology Congress 2025 (Switzerland)
- Case Reports in Hematology - Hematology Congress 2025 (Switzerland)
- Case reports of Hematology - HEMATOLOGY 2025 (Spain)
- CellTherapy - HEMATOLOGY 2025 (Spain)
- Clinical Haematology - Hematology Congress 2025 (Switzerland)
- Cord Blood Transplantation - Hematology Congress 2025 (Switzerland)
- COVID-19 and Hematology - HEMATOLOGY 2025 (Spain)
- Cutting-Edge Research in Blood Disorders - Blood Disorders 2025 (Italy)
- Digital Imaging in Hematology - Hematology Congress 2025 (Switzerland)
- Disorders of Vascular Bleeding - HEMATOLOGY 2025 (Spain)
- Future Trends in Hematology: Artificial Intelligence and Big Data - Blood Disorders 2025 (Italy)
- Gene Therapy and Genetic Engineering in Hematology - Blood Disorders 2025 (Italy)
- Haematology and Pharma Industry - Hematology Congress 2025 (Switzerland)
- Hematologic Cancers - Hematology Congress 2025 (Switzerland)
- Hematologic Toxicities and Side Effects of Cancer Therapy - Blood Disorders 2025 (Italy)
- Hematology - HEMATOLOGY 2025 (Spain)
- Hematology and Cardio-Oncology - Hematology Congress 2025 (Switzerland)
- Hematology in Global Health: Addressing Disparities - Blood Disorders 2025 (Italy)
- Hematology Nursing - Hematology Congress 2025 (Switzerland)
- Hematology Oncology - HEMATOLOGY 2025 (Spain)
- Hematology: Diagnostics and Screening - Hematology Congress 2025 (Switzerland)
- Hematopoietic Malignancies - Hematology Congress 2025 (Switzerland)
- Immunohematology - Hematology Congress 2025 (Switzerland)
- Immunohematology - HEMATOLOGY 2025 (Spain)
- Immunotherapy and Cellular Therapies in Hematology - Blood Disorders 2025 (Italy)
- Innovations in Red Blood Cell Disorders - Blood Disorders 2025 (Italy)
- Leukaemia and Lymphoma - HEMATOLOGY 2025 (Spain)
- Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation - HEMATOLOGY 2025 (Spain)
- Neuro-Hematology - Hematology Congress 2025 (Switzerland)
- New Drug Development in Hematology - HEMATOLOGY 2025 (Spain)
- Novel Diagnostic Techniques and Biomarkers in Hematology - Blood Disorders 2025 (Italy)
- Organ Specific Cancer - Hematology Congress 2025 (Switzerland)
- Patient Blood Management - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - Hematology Congress 2025 (Switzerland)
- Pediatric Hematology: Challenges and Innovations - Blood Disorders 2025 (Italy)
- Stem Cell Research - HEMATOLOGY 2025 (Spain)
- Stem Cell Therapy - Hematology Congress 2025 (Switzerland)
- Stem Cell Transplantation and Regenerative Medicine - Blood Disorders 2025 (Italy)
- Thalassemia - HEMATOLOGY 2025 (Spain)
- Therapeutic Apheresis - HEMATOLOGY 2025 (Spain)
- Thrombosis and Coagulation - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine: Advances and Challenge - Blood Disorders 2025 (Italy)
- Transfusion Medicines - Hematology Congress 2025 (Switzerland)
- Transfusion Transmissible Infections - HEMATOLOGY 2025 (Spain)
- Vascular Bleeding Disorders - Hematology Congress 2025 (Switzerland)